Woah, we’re halfway there…
Living on a prayer (and half a test set): Unblinding the data, freezing the board, and stepping into Phase 2. By Jon Swain, Maria Castellanos,
Peak Performance or Just Noise?
Statistical Comparison of Blind Challenge Entries by Jon Swain Benchmarks have become ubiquitous in machine learning, from the MNIST (Modified National Institute of Standards and
Predicting PXR Induction - We have liftoff
Launch details for the PXR induction challenge, including the dataset, rules, and practical guidance for participants.
Lessons Learned from the OpenADMET-ExpansionRx Blind Challenge: Can We Trust Zero-Shot ADMET Predictions?
Lessons and reflections from the OpenADMET-ExpansionRx blind challenge — evaluating whether zero-shot ADMET predictions can be trusted in real drug discovery settings.
Announcing the next OpenADMET Blind Challenge: Predicting PXR Induction
An introduction to the next blind challenge and why blinded datasets remain important for realistic benchmarking.
Lessons Learned from the OpenADMET - ExpansionRx Blind Challenge
Maria Castellanos Hugo MacDermott-Opeskin Jon Ainsley Pat Walters The ExpansionRx challenge, launched on October 27, 2025, closed two weeks ago! We are extremely grateful
The OpenADMET - ExpansionRx Blind Challenge has Come to an End
Maria Castellanos Hugo MacDermott-Opeskin Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties can make or break the preclinical and clinical development of small molecules.
OpenADMET - ExpansionRx Blind Challenge
Intermediate leaderboard release Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties can make or break the preclinical and clinical development of small molecules. At OpenADMET
Announcement 2: ExpansionRx - OpenADMET Blind Challenge
Additional details on the coming challenge Absorption, Distribution, Metabolism, Excretion and Toxicity–ADMET–properties can make or break preclinical and clinical development of small molecules.
Announcement 1: ExpansionRx-OpenADMET Blind Challenge
Small molecules continue to be the bricks and mortar of drug discovery globally, accounting for ~75% of FDA approvals over the last decade. Oral bioavailability,